Large scale genomic instability as an additive prognostic marker in early prostate cancer

Cellular Oncology

Volumn 31, Issue 4, 2009, Pages 251-259

  Pretorius, Maria E ^a,b   Wæhre, Hkon ^a,b   Abeler, Vera M ^a   Davidson, Ben ^a   Vlatkovic, Ljiljana ^a   Lothe, Ragnhild A ^a,b   Giercksky, Karl Erik ^a   Danielsen, Hvard E ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

DNA ploidy; Gleason; Prognosis; Prostate cancer; Radical prostatectomy

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; DIPLOIDY; EARLY CANCER; FOLLOW UP; GENOMIC INSTABILITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMAGE CYTOMETRY; MAJOR CLINICAL STUDY; MALE; MOSTOFI GRADING; PLOIDY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; TETRAPLOIDY; TREATMENT OUTCOME;

AGED; FOLLOW-UP STUDIES; GENOMIC INSTABILITY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLOIDIES; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 68149101191     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: 10.3233/CLO-2009-0463     Document Type: Article

References (39)

1. H. Baba, D. Korenaga, Y. Kakeji, M. Haraguchi, T. Okamura and Y. Maehara, DNA ploidy and its clinical implications in gastric cancer, Surgery 131 (2002), S63-S70.
2. A. Bantis, M. Gonidi, P. Athanassiades, C. Tsolos, A. Liossi, E. Aggelonidou, A.M. Athanassiadou, E. Petrakakou and P. Athanassiadou, Prognostic value of DNA analysis of prostate adenocarcinoma: correlation to clinicopathologic predictors, J. Exp. Clin. Concer Res. 24 (2005), 273-278.
3. M.L. Blute, O. Nativ, H. Zincke, G.M. Farrow, T. Therneau and M.M. Lieber, Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy, J. Urol. 142(1989), 1262-1265.
4. M. Borre, M. Hoyer, B. Nerstrom and J. Overgaard, DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure, Prostate 36 (1998), 244-249.
5. D.G. Bostwick, D.J. Grignon, M.E. Hammond, M.B. Amin, M. Cohen, D. Crawford, M. Gospadarowicz, R.S. Kaplan, D.S. Miller, R. Montironi, T.F. Pajak, A. Pollack, J.R. Srigley and J.W. Yarbro, Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999, Arch. Pathol. Lab. Med. 124 (2000), 995-1000.
6. D.A. Brinker, J.S. Ross, T.A. Tran, D.M. Jones and J.I. Epstein, Can ploidy of prostate carcinoma diagnosed on needle biopsy predict radical prostatectomy stage and grade?, J. Urol. 162 (1999), 2036-2039.
7. Cancer Registry of Norway IoPcR, Cancer in Norway 2004, 2006.
8. M.J. Carmichael, R.W. Veltri, A.W. Partin, M.C. Miller, P.C. Walsh and J.I. Epstein, Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease, J. Urol. 153 (1995), 1015-1019.
9. T.Y. Chan, A.W. Partin, P.C. Walsh and J.I. Epstein, Prognostic significance of Gleason score 3 + 4 versus Gleason score 4 + 3 tumor at radical prostatectomy, Urology 56 (2000), 823-827.
10. C. Deliveliotis, A. Skolarikos, A. Karayannis, V. Tzelepis, N. Trakas, E. Alargof and V. Protogerou, The prognostic value of p53 and DNA ploidy following radical prostatectomy, World J. Urol. 21 (2003), 171-176.
11. J.I. Epstein, M. Amin, L. Boccon-Gibod, L. Egevad, P.A. Humphrey, G. Mikuz, D. Newling, S. Nilsson, W. Sakr, J.R. Srigley, T.M. Wheeler and R. Montironi, Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens, Scand. J. Urol. Nephrol. Suppl. 216 (2005), 34-63.
12. J.I. Epstein, A.W. Partin, J. Sauvageot and P.C. Walsh, Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term, follow-up, Am. J. Surg. Pathol. 20 (1996), 286-292.
13. G. Forsslund and A. Zetterberg, Ploidy level determinations in high-grade and low-grade malignant variants of prostatic carcinoma, Cancer Res. 50 (1990), 4281-4285.
14. T. Fujiwara, M. Bandi, M. Nitta, E.V. Ivanova, R.T. Bronson and D. Pellman, Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells, Nature 437 (2005), 1043-1047.
15. D.F. Griffiths, J. Melia, L.J. McWilliam, R.Y. Ball, K. Grigor, P. Harnden, M. Jarmulowicz, R. Montironi, R. Moseley, M. Waller, S. Moss and M.C. Parkinson, A study of Gleason score interpretation in different groups of UK pathologists; techniques for improving reproducibility, Histopathology 48 (2006), 655-662.
16. M. Haggman, T.M. de la, S. Brandstedt, B.J. Norlen, M. Norberg and C. Busch, Pre- and postoperative DNA ploidy patterns correlated to pT-stage, histological grade and tumour volume in total prostatectomy specimens, Scand. J. Urol. Nephrol. 28 (1994), 59-66.
17. M. Han, A.W. Partin, C.R. Pound, J.I. Epstein and P.C. Walsh, Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience, Urol. Clin. N. Am. 28 (2001), 555-565.
18. G. Haroske, J.P. Baak, H. Danielsen, F. Giroud, A. Gschwendtner, M. Oberholzer, A. Reith, P. Spieler and A. Booking, Fourth updated ESACP consensus report on diagnostic DNA image cytometry, Anal. Cell. Pathol. 23 (2001), 89-95.
19. D.W. Hedley, M.L. Friedlander, I.W. Taylor, C.A. Rugg and E.A. Musgrove, Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry, J. Histochem. Cytochem. 31 (1983), 1333-1335.
20. L. Holmberg, A. Bill-Axelson, F. Helgesen, J.O. Salo, P. Folmerz, M. Haggman, S.O. Andersson, A. Spangberg, C. Busch, S. Nordling, J. Palmgren, H.O. Adami, J.E. Johansson and B.J. Norlen, A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer, N. Engl. J. Med. 347 (2002), 781-789.
21. P.A. Humphrey, P.J. Walther, S.M. Currin and R.T. Vollmer, Histologic grade, DNA ploidy, and intraglandular tumor extent as indicators of tumor progression of clinical stage B prostatic carcinoma. A direct comparison, Am. J. Surg. Pathol. 15 (1991), 1165-1170.
22. G.B. Kristensen, W. Kildal, V.M. Abeler, J. Kaern, I. Vergote, C.G. Trope and H.E. Danielsen, Large-scale genomic instability predicts long-term, outcome for women with invasive stage I ovarian cancer, Ann. Oncol. 14 (2003), 1494-1500.
23. S.E. Lerner, T.M. Seay, M.L. Blute, E.J. Bergstralh, D. Barrett and H. Zincke, Prostate specific antigen detected prostate cancer (clinical stage TIc): an interim analysis, J. Urol. 155 (1996), 821-826.
24. J.M. Martinez-Jabaloyas, J.L. Ruiz-Cerda, M. Hernandez, A. Jimenez and F. Jimenez-Cruz, Prognostic value of DNA ploidy and nuclear morphometry in prostate cancer treated with androgen deprivation, Urology 59 (2002), 715-720.
25. B.T. Montgomery, O. Nativ, M.L. Blute, G.M. Farrow, R.P. Myers, H. Zincke, T.M. Therneau and M.M. Lieber, Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis, Arch. Surg. 125 (1990), 327-331.
26. R. Montironi, R. Mazzuccheli, M. Scarpelli, A. Lopez-Beltran, G. Fellegara and F. Algaba, Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies, BJU Int. 95 (2005), 1146-1152.
27. L.B. Mora, L.C. Moscinski, J.I. Diaz, P. Blair, A.B. Cantor and J.M. Pow-Sang, Stage B prostate cancer: Correlation of DNA ploidy analysis with histological and clinical parameters, Cancer Control 6 (1999), 587-591.
28. J.M. Peters, B.J. Miles, J.J. Kubus and J.D. Crissman, Prognostic significance of the nuclear DNA content in localized prostatic adenocarcinoma, Anal. Quant. Cytol. Histol. 12 (1990), 359-365.
29. F.R. Ribeiro, R. Henrique, A.T. Martins, C. Jeronimo and M.R. Teixeira, Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients, Eur. Urol. 52 (2007), 116-125.
30. F.R. Ribeiro, C. Jeronimo, R. Henrique, D. Fonseca, J. Oliveira, R.A. Lothe and M.R. Teixeira, 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from, prostate cancer suspects, Clin. Cancer Res. 12 (2006), 3961-3970.
31. A.W. Ritchie, F. Dorey, L.J. Layfield, J. Hannah, H. Lovrekovich and J.B. deKernion, Relationship of DNA content to conventional prognostic factors in clinically localised carcinoma of the prostate, Br. J. Urol. 62 (1988), 245-260.
32. J.S. Ross, H. Figge, H.X. Bui, A.D. del Rosario, T.A. Jennings, M.D. Rifkin and H.A. Fisher, Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer, Cancer 74 (1994), 2811-2818.
33. J.S. Ross, H.L. Figge, H.X. Bui, A.D. del Rosario, H.A. Fisher, T. Nazeer, T.A. Jennings, R. Ingle and D.N. Kim, E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome, Mod. Pathol. 7 (1994), 835-841.
34. J.S. Ross, CE. Sheehan, R.A. Ambros, T. Nazeer, T.A. Jennings, R.P. Kaufman, Jr., H.A. Fisher, M.D. Rifkin and B.V. Kallakury, Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer, Am. J. Surg. Pathol. 23 (1999), 296-301.
35. Q. Shi and R.W. King, Chromosome nondisjunction, yields tetraploid rather than aneuploid cells in human cell lines, Nature 437 (2005), 1038-1042.
36. J.A. Smith Jr., A.D. Hernandez, C.J. Wittwer, J.M. Avent, J. Greenwood, E.H. Hammond and R.G. Middleton, Long-term follow-up after radical prostatectomy. Identification of prognostic variables, Urol. Clin. N. Am. 18 (1991), 473-476.
37. J.S. Tucci, W. Blumenfeld and P. Narayan, Ploidy status correlates with outcome in stage B prostate adenocarcinoma, Braz. J. Med. Biol. Res. 27 (1994), 25-32.
38. R.W. Veltri, A.W. Partin, J.E. Epstein, G.M. Marley, C.M. Miller, D.S. Singer, K.P. Patton, S.R. Criley and D.S. Coffey, Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression, J. Cell. Biochem. 19(Suppl.) (1994), 249-258.
39. M.P. Wirth, H.A. Muller, A. Manseck, J. Muller and H.G. Frohmuller, Value of nuclear DNA ploidy patterns in patients with prostate cancer after radical prostatectomy, Eur. Urol. 20 (1991), 248-252.